Henry Schein Inc. (HSIC) Rating Lowered to Neutral at Robert W. Baird
Henry Schein Inc. (NASDAQ:HSIC) was downgraded by investment analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report released on Friday. They currently have a $164.00 price target on the stock, down from their previous price target of $176.00. Robert W. Baird’s price target suggests a potential upside of 7.04% from the company’s previous close.
Several other equities research analysts have also recently commented on HSIC. Zacks Investment Research raised Henry Schein from a “sell” rating to a “hold” rating in a report on Wednesday, October 5th. Bank of America Corp. assumed coverage on Henry Schein in a report on Monday, September 12th. They issued a “buy” rating and a $185.00 price target for the company. Finally, Goldman Sachs Group Inc. raised Henry Schein from a “neutral” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, October 11th. One research analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $159.50.
Shares of Henry Schein (NASDAQ:HSIC) opened at 153.21 on Friday. The company has a market capitalization of $12.53 billion, a price-to-earnings ratio of 25.95 and a beta of 1.05. The firm’s 50-day moving average price is $161.88 and its 200-day moving average price is $169.89. Henry Schein has a 12 month low of $142.64 and a 12 month high of $183.00.
Henry Schein (NASDAQ:HSIC) last announced its earnings results on Thursday, August 4th. The company reported $1.64 EPS for the quarter, beating analysts’ consensus estimates of $1.63 by $0.01. Henry Schein had a return on equity of 17.84% and a net margin of 4.42%. The business earned $2.87 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the prior year, the firm earned $1.46 earnings per share. The business’s revenue was up 9.3% compared to the same quarter last year. Equities research analysts expect that Henry Schein will post $6.57 EPS for the current year.
In other news, Director Paul Brons sold 3,381 shares of the firm’s stock in a transaction on Monday, August 29th. The stock was sold at an average price of $164.03, for a total transaction of $554,585.43. Following the completion of the transaction, the director now directly owns 13,715 shares in the company, valued at $2,249,671.45. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 1.27% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurich Insurance Group Ltd FI bought a new position in Henry Schein during the first quarter worth about $3,204,000. National Pension Service raised its position in Henry Schein by 4.4% in the first quarter. National Pension Service now owns 56,059 shares of the company’s stock worth $9,677,000 after buying an additional 2,383 shares during the period. AMP Capital Investors Ltd raised its position in Henry Schein by 1.7% in the first quarter. AMP Capital Investors Ltd now owns 23,958 shares of the company’s stock worth $4,141,000 after buying an additional 400 shares during the period. Citizens Financial Group Inc RI raised its position in Henry Schein by 1.0% in the first quarter. Citizens Financial Group Inc RI now owns 46,377 shares of the company’s stock worth $8,006,000 after buying an additional 452 shares during the period. Finally, Prudential PLC raised its position in Henry Schein by 57.5% in the first quarter. Prudential PLC now owns 6,300 shares of the company’s stock worth $1,088,000 after buying an additional 2,300 shares during the period. Hedge funds and other institutional investors own 92.03% of the company’s stock.
Henry Schein Company Profile
Henry Schein, Inc is a provider of health care products and services to office-based dental, animal health and medical practitioners. The Company’s segments include healthcare distribution, and technology and value-added services. The healthcare distribution segment aggregates its global dental, animal health and medical operating segments.
Receive News & Stock Ratings for Henry Schein Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein Inc. and related stocks with our FREE daily email newsletter.